Coherus Oncology, Inc. (CHRS) fundamentals score
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 3.5 out of 10, Weak long-term fundamentals
- Growth: 3.0/10
- Profitability: 3.6/10
- Financial health: 4.3/10
- Earnings quality: 1.3/10
- Valuation: 5.5/10
Scores are calculated from Coherus Oncology, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10